13.03.2013 - British Shire plc has broadened its therapeutic scope to neonatology by the strategic acquisition of Swedish Premacure AB of Uppsala.
The privately held biotech company is running a dose finding, safety and efficacy Phase II programme for the most common cause of visual loss in childhood – the prevention of retinopathy of prematurity (ROP). Currently, only symptomatic treatment is available for ROP. Shire will purchase Premacure for an undisclosed upfront fee and success-dependent milestones.
In ROP, preterm infants (born before 31 weeks of gestation) lack specific growth factors, such as insulin-like growth factor 1 (IGF-1), which supports normal childhood development and which is involved in ROP. The Swedish have developed a first-in-class recombinant protein replacement therapy termed rhIGF-I/rhIGFBP-3 (insulin-like growth factor-1 binding protein-3) for the orphan disease. The company believes administration of IGF-1 to premature infants, as a substitute for the maternal and endogenous source, allows for the establishment of a physiological level of the hormone comparable to that present in utero.
Shire said it will continue the ongoing Phase II study, the primary goal of which is to restore the IGF-1 levels in preterm infants to those found during normal in utero development. „ We will build on the work that Premacure has done and will apply Shire’s proven ability in developing protein replacement therapies for rare disorders to bring this much needed therapy to the market,” said Flemming Ornskov, CEO Designate of Shire. The treatment targets a patient population of 1,100–1,500 in the US alone .
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.